Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

uridine triacetate

(YOOR-ih-deen try-A-seh-tayt)
A drug used in the emergency treatment of adults and children who receive too much fluorouracil or capecitabine or who have heart or central nervous system toxicity or other serious side effects that occur within 4 days of ending treatment with these drugs. Uridine triacetate may help protect healthy cells from some of the side effects caused by certain anticancer drugs. It is a type of chemoprotective agent and a type of pyrimidine analog. Also called PN401, triacetyluridine, and Vistogard.
Search NCI's Dictionary of Cancer Terms